Literature DB >> 20137773

Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets.

Bettina Lorenz-Depiereux1, Dirk Schnabel, Dov Tiosano, Gabriele Häusler, Tim M Strom.   

Abstract

The analysis of rare genetic disorders affecting phosphate homeostasis led to the identification of several proteins that are essential for the renal regulation of phosphate homeostasis; for example, fibroblast growth factor 23 (FGF23), which inhibits renal phosphate reabsorption and 1,25-dihydroxyvitamin D synthesis. Here, we report presumable loss-of-function mutations in the ENPP1 gene (ectonucleotide pyrophosphatase/phosphodiesterase) in members of four families affected with hypophosphatemic rickets. We provide evidence for the conclusion that ENPP1 is the fourth gene-in addition to PHEX, FGF23, and DMP1-that, if mutated, causes hypophosphatemic rickets resulting from elevated FGF23 levels. Surprisingly, ENPP1 loss-of-function mutations have previously been described in generalized arterial calcification of infancy, suggesting an as yet elusive mechanism that balances arterial calcification with bone mineralization. Copyright (c) 2010 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20137773      PMCID: PMC2820166          DOI: 10.1016/j.ajhg.2010.01.006

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  16 in total

Review 1.  Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family.

Authors:  James W Goding; Bert Grobben; Herman Slegers
Journal:  Biochim Biophys Acta       Date:  2003-05-20

2.  Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.

Authors:  Yuji Yamazaki; Ryo Okazaki; Minako Shibata; Yukihiro Hasegawa; Kohei Satoh; Toshihiro Tajima; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Takeyoshi Yamashita; Seiji Fukumoto
Journal:  J Clin Endocrinol Metab       Date:  2002-11       Impact factor: 5.958

3.  Mutations in ANKH cause chondrocalcinosis.

Authors:  Adrian Pendleton; Michelle D Johnson; Anne Hughes; Kyle A Gurley; Andrew M Ho; Michael Doherty; Josh Dixey; Pierre Gillet; Damien Loeuille; Rodney McGrath; Antonio Reginato; Rita Shiang; Gary Wright; Patrick Netter; Charlene Williams; David M Kingsley
Journal:  Am J Hum Genet       Date:  2002-09-20       Impact factor: 11.025

4.  Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3.

Authors:  Bettina Lorenz-Depiereux; Anna Benet-Pages; Gertrud Eckstein; Yardena Tenenbaum-Rakover; Janine Wagenstaller; Dov Tiosano; Ruth Gershoni-Baruch; Norbert Albers; Peter Lichtner; Dirk Schnabel; Ze'ev Hochberg; Tim M Strom
Journal:  Am J Hum Genet       Date:  2005-12-09       Impact factor: 11.025

5.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

6.  Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy.

Authors:  Frank Rutsch; Petra Böyer; Yvonne Nitschke; Nico Ruf; Bettina Lorenz-Depierieux; Tanja Wittkampf; Gabriele Weissen-Plenz; Rudolf-Josef Fischer; Zulf Mughal; John W Gregory; Justin H Davies; Chantal Loirat; Tim M Strom; Dirk Schnabel; Peter Nürnberg; Robert Terkeltaub
Journal:  Circ Cardiovasc Genet       Date:  2008-12

7.  A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium.

Authors: 
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

8.  Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification.

Authors:  Frank Rutsch; Nico Ruf; Sucheta Vaingankar; Mohammad R Toliat; Anita Suk; Wolfgang Höhne; Galen Schauer; Mandy Lehmann; Tony Roscioli; Dirk Schnabel; Jörg T Epplen; Alex Knisely; Andrea Superti-Furga; James McGill; Marco Filippone; Alan R Sinaiko; Hillary Vallance; Bernd Hinrichs; Wendy Smith; Merry Ferre; Robert Terkeltaub; Peter Nürnberg
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

9.  Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.

Authors:  Erik A Imel; Munro Peacock; Pisit Pitukcheewanont; Howard J Heller; Leanne M Ward; Dorothy Shulman; Moustapha Kassem; Paula Rackoff; Mark Zimering; Alan Dalkin; Elaine Drobny; Giacomo Colussi; Joseph L Shaker; Elizabeth H Hoogendoorn; Siu L Hui; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2006-03-21       Impact factor: 5.958

10.  Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine.

Authors:  A Okawa; I Nakamura; S Goto; H Moriya; Y Nakamura; S Ikegawa
Journal:  Nat Genet       Date:  1998-07       Impact factor: 38.330

View more
  140 in total

Review 1.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

Review 2.  The expanding family of hypophosphatemic syndromes.

Authors:  Thomas O Carpenter
Journal:  J Bone Miner Metab       Date:  2011-12-14       Impact factor: 2.626

3.  Evaluation of hypophosphatemia: lessons from patients with genetic disorders.

Authors:  Justine Bacchetta; Isidro B Salusky
Journal:  Am J Kidney Dis       Date:  2011-11-09       Impact factor: 8.860

4.  Efficacy and safety of 2-year etidronate treatment in a child with generalized arterial calcification of infancy.

Authors:  Thomas Edouard; Gilles Chabot; Joaquim Miro; Daniela Christina Buhas; Yvonne Nitschke; Chantale Lapierre; Frank Rutsch; Nathalie Alos
Journal:  Eur J Pediatr       Date:  2011-09-20       Impact factor: 3.183

Review 5.  Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism.

Authors:  L Darryl Quarles
Journal:  Nat Rev Endocrinol       Date:  2012-01-17       Impact factor: 43.330

6.  Novel NaPi-IIc mutations causing HHRH and idiopathic hypercalciuria in several unrelated families: long-term follow-up in one kindred.

Authors:  Y Yu; S R Sanderson; M Reyes; A Sharma; N Dunbar; T Srivastava; H Jüppner; C Bergwitz
Journal:  Bone       Date:  2012-02-24       Impact factor: 4.398

7.  It ANKH necessarily so.

Authors:  Michael T Collins; Manfred Boehm
Journal:  J Clin Endocrinol Metab       Date:  2011-01       Impact factor: 5.958

8.  1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression.

Authors:  Eva S Liu; Janaina S Martins; Adalbert Raimann; Byongsoo Timothy Chae; Daniel J Brooks; Vanda Jorgetti; Mary L Bouxsein; Marie B Demay
Journal:  J Bone Miner Res       Date:  2016-02-02       Impact factor: 6.741

Review 9.  FGF23 and Phosphate Wasting Disorders.

Authors:  Xianglan Huang; Yan Jiang; Weibo Xia
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

Review 10.  The Causes of Hypo- and Hyperphosphatemia in Humans.

Authors:  Eugénie Koumakis; Catherine Cormier; Christian Roux; Karine Briot
Journal:  Calcif Tissue Int       Date:  2020-04-13       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.